

Michel R Langlois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4007643/publications.pdf>

Version: 2024-02-01

28
papers

1,939
citations

516710

16
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

3194
citing authors

#	ARTICLE	IF	CITATIONS
1	Concordance of apolipoprotein B concentration with the Friedewald, Martin-Hopkins, and Sampson formulas for calculating LDL cholesterol. <i>Biochemia Medica</i> , 2022, 32, 51-61.	2.7	2
2	The CCA Special Issue on Cardiovascular Markers. <i>Clinica Chimica Acta</i> , 2021, 512, 121.	1.1	0
3	Update on apolipoprotein B. <i>Current Opinion in Lipidology</i> , 2021, 32, 226-230.	2.7	25
4	How Well Do Laboratories Adhere to Recommended Guidelines for Cardiac Biomarkers Management in Europe? The CARdiac MARker Guideline Uptake in Europe (CAMARGUE) Study of the European Federation of Laboratory Medicine Task Group on Cardiac Markers. <i>Clinical Chemistry</i> , 2021, 67, 1144-1152.	3.2	7
5	Investigations on the clinical utility of apolipoprotein B measurement: A research priority. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1252-1254.	1.8	2
6	Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 496-517.	2.3	119
7	Evolving concepts on the management of dyslipidaemia. <i>Acta Clinica Belgica</i> , 2020, 75, 80-90.	1.2	3
8	How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CARdiac MARker Guideline Uptake in Europe (CAMARGUE) study. <i>Clinica Chimica Acta</i> , 2020, 508, 267-272.	1.1	13
9	Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. <i>Current Cardiology Reports</i> , 2020, 22, 67.	2.9	42
10	Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. <i>Atherosclerosis</i> , 2020, 294, 46-61.	0.8	137
11	Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MARker guideline Uptake in Europe (CARMAGUE) study. <i>Clinica Chimica Acta</i> , 2020, 511, 59-66.	1.1	6
12	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
13	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. <i>Current Cardiology Reports</i> , 2018, 20, 88.	2.9	18
14	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	5.8	238
15	Are Heart Failure Management Recommendations and Guidelines Followed in Laboratory Medicine in Europe and North America? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) Study. <i>Journal of Applied Laboratory Medicine</i> , 2017, 1, 483-493.	1.3	5
16	How Well Do Laboratories Adhere to Recommended Clinical Guidelines for the Management of Myocardial Infarction: The CARdiac MARker Guidelines Uptake in Europe Study (CARMAGUE). <i>Clinical Chemistry</i> , 2016, 62, 1264-1271.	3.2	49
17	Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut-points—A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2016, 62, 930-946.	3.2	145
18	Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. <i>European Heart Journal</i> , 2016, 37, 1944-1958.	2.2	542

#	ARTICLE	IF	CITATIONS
19	Arterial stiffness and influences of the metabolic syndrome: A cross-countries study. <i>Atherosclerosis</i> , 2014, 233, 654-660.	0.8	116
20	Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. <i>Atherosclerosis</i> , 2014, 233, 83-90.	0.8	52
21	Serum amyloid A is independently related to apolipoprotein A-I but not to HDL-cholesterol in patients with angina pectoris. <i>Clinical Biochemistry</i> , 2013, 46, 1660-1663.	1.9	6
22	Accuracy of three automated 25-hydroxyvitamin D assays in hemodialysis patients. <i>Clinica Chimica Acta</i> , 2013, 415, 255-260.	1.1	42
23	Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. <i>Atherosclerosis</i> , 2013, 226, 296-298.	0.8	6
24	Inflammation Markers in Patients with Cardiovascular Disease and Metabolic Syndrome. <i>Journal of Medical Biochemistry</i> , 2013, 32, 214-219.	1.7	11
25	Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1169-81.	2.3	11
26	Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment. <i>Clinica Chimica Acta</i> , 2010, 411, 1361-1366.	1.1	21
27	Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 128-37.	2.3	101
28	Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2006, 369, 168-178.	1.1	31